Courtenay Brinckerhoff is a partner and intellectual property lawyer with Foley & Lardner LLP. Ms. Brinckerhoff’s practice focuses on client counseling in all aspects of obtaining, licensing and enforcing patents and conducting freedom-to-operate and due diligence investigations. She is chair of the firm’s IP Law and Practice committee, immediate past vice chair of the firm’s Chemical, Biotechnology & Pharmaceutical Practice and a member of the firm's Patent Trials group, Appellate Practice and Life Sciences Industry Team. She also is involved with Foley’s Medical Device Initiative and Nutraceuticals Team. Ms. Brinckerhoff is the editor and primary author for Foley’s PharmaPatentsBlog.com.
Over the past 20 years, Ms. Brinckerhoff has represented clients before the U.S. Patent Office, the Patent Trial and Appeal Board, and the U.S. Court of Appeals for the Federal Circuit, and has been involved in complex patent matters, including a four-party interference, Inter Partes Reexaminations, Inter Partes Reviews, and ANDA litigation.
Ms. Brinckerhoff works with clients in diverse industries, including pharmaceuticals (chemical and biotechnological), human and animal food products, nutraceuticals, and medical devices. She has particular experience with transdermal pharmaceutical products (patches, gels, and liquids), oral dosage forms (including controlled/extended release formulations), enzyme-based technologies, diagnostic and therapeutic antibodies, active and passive immunization therapies, and personalized medicine.
She has served as vice chair of the firm’s Chemical, Biotechnology & Pharmaceutical Practice and is an active member of the firm's Appellate Practice and Life Sciences Industry Team.
More Legal and Business Bylines From Courtenay C. Brinckerhoff
- Supreme Court Won’t Hear Skinny Label Case - (Posted On Tuesday, May 16, 2023)
- Federal Circuit Considers Patentability of Overlapping Ranges - (Posted On Tuesday, May 16, 2023)
- Another Letter From Congress Complaining About Pharmaceutical Patents - (Posted On Monday, May 01, 2023)
- Significant New USPTO Fees Proposed for 2025 - (Posted On Monday, April 24, 2023)
- USPTO To Transition To Electronically Granted Patents In April 2023 - (Posted On Thursday, March 02, 2023)
- Federal Circuit Weighs In On Patent Eligibility Of Isolated Vitamin - (Posted On Thursday, February 23, 2023)
- Senate Judiciary Committee Pushes Pharma Patents and Pricing Bills Forward - (Posted On Monday, February 13, 2023)
- Unleashing American Innovators Act Slashes USPTO Small Entity Fees - (Posted On Wednesday, January 04, 2023)
- USPTO Delays Fee For Non-DOCX Applications - (Posted On Thursday, December 29, 2022)
- USPTO Continues Discussion of Pharmaceutical Patents - (Posted On Tuesday, November 15, 2022)
Courtenay C. Brinckerhoff and her work on Foley & Lardner's Pharma Patents blog has been selected for a National Law Review Go-To Thought Leadership Award. Ms. Brinckerhoff offers expert analysis on an area of law that can be very complicated, breaking down developments at the U.S. Patent Office, the Patent Trial and Appeal Board, and the U.S. Court of Appeals for the Federal Circuit. Her insights on patent litigation, especially pharmaceutical patents, and how decisions impact the larger landscape are of particular interest to our readers. You can subscribe to Foley & Lardner's blog, PharmaPatents, here.